Clinical Trial Update: A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer [Phase 1]

View source ↗

Summary

This Phase 1 study evaluates AMG 757 in neuroendocrine prostate cancer and has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Prostate Cancer

Drugs mentioned

• AMG 757

Snippet

Sponsor: Amgen | Conditions: Neuroendocrine Prostate Cancer | Phase 1 | Status: COMPLETED | Results posted: 2025-09-12